Novel Class of Central Renin Angiotensin Aldosterone System Inhibitor: Firibastat

ABSTRACT

Hypertension is one of the most important risk factors for the development of ischemic heart diseases, stroke, disability, vascular demen?a, heart failure, renal dysfunc?on, re?nopathy, and premature death. Despite the use of two or more blood pressure lowering medica?ons, a considerable propor?on of pa?ents show poor control. Current an?hypertensive medica?ons show the limita?on of use and effect in obese popula?on, certain races like black popula?on and also in renal impairment. Thus, there is an impending need to develop novel classes of an?hypertensive agents ac?ng on new targets with diversified mechanisms of ac?on to more effec?vely manage raised blood pressure. With the introduc?on of the recent concept of overac?ve brain renin angiotensin system in cardiovascular disorders, a?empts have been made to iden?fy a molecule with the poten?al of inhibi?ng aminopep?dases involved in the forma?on of Angiotensin III. A novel aminopep?dase A inhibitor, also a prodrug Firibastat is currently undergoing development in Phase III clinical trials for hypertension as well as chronic heart failure. We hereby, provide an updated summary of evidence generated so far with Firibastat and also a glimpse into the therapeu?c poten?al of this novel candidate extending beyond the spectrum of essen?al hypertension